TDPel Media News Agency

AI technology to halve new drug development period

Fact Checked by TDPel News Desk
By Pelumi Emmanuel

The technology of artificial intelligence will be used in every step of developing drugs to cut the time it takes to discover a new drug in half, the newly appointed leader of the Korea AI Center for Drug Discovery and Development said Wednesday.

“Starting from designing candidate substances, AI technology can set up clinical trials based on biometric data and minimize uncertainty, time and cost by deriving the optimal patient group,” said Kim Woo-youn, head of KAICD at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in an online press conference.

Referring to the KAICD’s survey, he underlined that the number of local AI startups in the field of developing new drugs reached 38. Of them, 14 received investments worth of 170 billion won ($140 million) in the first half of last year, he added.

“But it’s only in the premature stage. The priority of the AI new drug development market is to come up with a precedent that shows the application of AI technology has cut down the cost of (research and development) by this much,” said Kim.

In efforts to better cooperation between the country’s AI technology and drug development sectors, the KAICD head unveiled the plan to launch an AI platform for researchers developing new drugs in the second half of this year.

The online platform will offer easier access and understanding of AI technology for pharmaceutical chemists who do not have professional knowledge of AI, he said.

Kim added that the KAICD is in the process of setting up a website that provides all-in-one information about AI technology from in and out of the country and AI companies. The website is expected to start running from May.

Pointing out that South Korea’s level of AI technology is recognized on the global stage, he called for the need to lay out more chances of collaboration for drug makers and AI companies.

“If a national-level consortium encompassing industry, academia, research and hospitals is established, the AI new drug development business will surely accelerate,” said Kim.

Spread the News. Auto-share on
Facebook Twitter Reddit LinkedIn
10
We are taking you to the next article automatically...You can cancel it below or click Load Now to read it now!
Pelumi Emmanuel

About Pelumi Emmanuel

Pelumi Emmanuel is an accomplished writer and journalist with over 15 years of experience in the industry. He is a passionate and dedicated professional who is committed to producing high-quality content that informs, engages, and entertains readers. Pelumi’s love for reading and writing is evident in his work, which has been read worldwide and has garnered him a loyal following. His journalistic expertise is matched only by his natural talent for storytelling, making his articles both informative and engaging. He lives in California, USA.